by Truveta staff | May 21, 2025 | Research
A recent analysis using Truveta Data reveals that patients undergoing high-risk, non-emergency heart procedures (percutaneous coronary intervention, or PCI) with support from the Impella heart pump had better outcomes than those supported with an intra-aortic balloon...
by Truveta staff | Feb 26, 2025 | Research
Heart failure with reduced ejection fraction (HFrEF) remains a leading cause of morbidity and mortality. While guideline-directed medical therapy (GDMT) has been shown to improve left ventricular ejection fraction (LVEF), real-world data on LVEF recovery and GDMT...
by Truveta News | Nov 14, 2024 | News
Truveta Data, the most complete, timely, and clean electronic health record (EHR) data, now includes more than 120 million de-identified patients – more than one-third of the U.S. population – empowering researchers to study patients representative of the diversity of...
by Truveta staff | Sep 26, 2024 | Technology
Despite advances in guideline-directed medical therapy, heart failure (HF) readmission rates have worsened over the past decade. Optimizing acute inpatient decongestion is critical in mitigating HF morbidity and mortality, but few new treatment strategies have emerged...
by Truveta staff | May 2, 2024 | Research
Leading heart failure researchers have published new research in JACC: Heart Failure. The TREAT-AHF study found that despite significant efforts to improve acute heart failure treatment over the past 20 years, management remains unchanged. Reprieve Cardiovascular is...
